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Abstract
Background: For persons with multiple sclerosis (MS) it is important to preserve their autonomy, in spite of
increasing disability. A major factor mediating autonomy is self-efficacy. According to the social cognitive theory
stressors are crucial determinants of self-efficacy, as well as the interaction with partners.
Methods: In an explorative observational study we assessed in 47 persons with MS (PwMS) the effect of an intense,
multidisciplinary, 3-day, social cognitive wellness program with the participation of support partners, after 1, 3 and
6 months. Primary outcomes: self-efficacy-control and -function (Multiple Sclerosis Self-Efficacy Scale [MSSES]),
limitations to and problems with participation and autonomy (Impact on Participation and Autonomy [IPA] scale).
Secondary outcomes: health-related quality of life (HRQoL) (MS Quality of Life-54 Items [MSQoL-54] questionnaire),
anxiety, depression (Hospital Anxiety and Depression Scale [HADS]), and fatigue (Modified Fatigue Impact Scale-5
Items [MFIS-5]). Disability was measured with the Expanded Disability Status Scale (EDSS). Percentage changes from
baseline were tested with T-tests, level of significance 0.05.
Results: In the whole group the MSQoL-54 Mental score was increased at 1, 3 and 6 months (+16.0%, +13.2%,
+12.2%), and the MSQoL-54 Physical (+10.2%) at 6 months, with no changes in other outcomes. The relapsing
remitting (RR) subgroup (n = 20) had at 6 months an increase in the MSSES-Control score (+24.8%) and in the
MSQoL54 Mental and Physical scores (+22.3%, +17.6%). Progressive patients (n = 22) only showed an increase in the
MSQoL-54 Mental score (+11.5%) at 1 month. In the low-disability (EDSS < 4.0) subgroup the MSSES-Control score
was increased (+23.8%) at 6 months, and the IPA-Limitations and -Problems scores decreased at 3 months
(−6.1%, −8.8%); the MSQoL-54 Mental score had increased at 1, 3 and 6 months (+19.3%, +21.5%, +19.3%). In the
high-disability (EDSS > =4.0) subgroup no significant changes occurred.
Conclusions: Results from this observational study suggest that 6 months after an intense, 3-day, multidisciplinary,
social cognitive wellness program with support partners, PwMS with a RR course or low disability may experience
an improved self-efficacy-control and HRQoL.
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Background
Multiple sclerosis (MS) is a chronic inflammatory and de-
generative disease of the central nervous system (CNS). In
about 80% of the persons with MS (PwMS) the initial
phase is clinically characterized by relapses followed by a
complete or partial recovery: relapsing remitting MS
(RRMS). Although disease modifying drugs (DMDs) de-
crease the frequency and severity of relapses, the disease
course remains largely unpredictable. After 10 to 15 years
RRMS frequently progresses to secondary progressive MS
(SPMS), that is characterized by a slow unceasing increase
in disability. It is uncertain to what extent DMD treatment
of RRMS may prevent or postpone SPMS. About 15% of
PwMS have a progressive course from disease onset: pri-
mary progressive MS (PPMS). In both SPMS and PPMS
DMDs are not effective.
Most PwMS get increasingly disabled in the course of
the disease, with disabilities negatively affecting people’s
independence. Moreover, the negative experience of los-
ing independence has a negative impact on self-efficacy.
Self-efficacy is a psychological concept that refers to the
degree in which a person is confident to complete tasks
and reach goals in specific situations [1]. It is a core com-
ponent in social cognitive theory, in which psychosocial
functioning is determined by reciprocal interactions be-
tween personal factors, behavior, and the environment
[2,3]. Low self-efficacy has been associated with lower
health-related quality of life (HRQoL) [4,5], less psycho-
logical adjustment [6], and less physical activity [5]. Since
a lowered self-efficacy causes PwMS to undervalue their
actual capabilities, a vicious circle may start and still exist-
ing functions run a risk to eventually disappear.
Partners and other informal caregivers, like household
and family members, friends and neighbors, have also to
deal with the consequences of worsening disabilities and
a diminishing self-efficacy in PwMS. A constant and grow-
ing appeal by PwMS on their support partners results in
an increasing mental and physical strain of the latter, and
may seriously weigh on the mutual relation.
A wellness program is a structured intervention focused
on achieving wellness in the physical, psychological and
spiritual realm [7]. In the U.S.A., Can Do MS, a publically
accessible nonprofit wellness program, offers concentrated
4-day interdisciplinary educational wellness programs for
PwMS, that promote health seeking behaviors, lifestyle
empowerment, and wellness including exercise, and
with optional participation of support partners [8]. This
educational Can Do MS Program (CDP) has been devel-
oped to enable PwMS the uncovering of their existing
capabilities [8]. Recently Ng et al. observed an improve-
ment in self-efficacy and perceived health after CDP [8].
Although a complementary program for participants’
support partners was an integral part of this CDP, it is
unclear whether such participation was mandatory and
if not, to what extent support partners did participate in
the program.
In view of the positive results of the educational CDP
reported by Ng et al., the central role of self-efficacy in
social cognitive theory, and the importance of optimal
relations between PwMS and their support partners, we
set ourselves to assess the effect of a Social Cognitive Can
Do program (SCDP) with the participation of support
partners. Our primary intention was to exploratively in-
vestigate whether changes in self-efficacy, autonomy and
participation could be observed after SCDP (proof of con-
cept) and at what time points eventual changes were most
prominent. Secondarily, we assessed changes in HRQoL,
anxiety, depression, and fatigue, and also performed separ-
ate analyses for persons with RRMS, progressive MS, low
disability (Expanded Disability Status Scale [EDSS] < 4.0)
and high disability (EDSS > =4.0).
Methods
Social cognitive can do program
Concept
The goal of the SCDP is to uncover and promote exist-
ing capabilities, with the notion ‘stressor’ as central con-
cept. It is primarily a sociologically oriented approach, as
it tries to identify stressors that confine PwMS to their
physical, psychological or social roles. To reduce these
stressors, SCDP is based on the following principles:
identification and reduction of existing stressors; client-
centeredness; inclusion of the partner or another signifi-
cant informal caregiver; group sessions; and self-reliance,
autonomy, and acceptance as central themes. Accord-
ingly, SCDP focuses on the exploration of stressors that
confine PwMS to their disease and their limitations; re-
duces relevant stressors; explores and pushes personal
boundaries; and creates new personal boundaries by mak-
ing optimal use of the existing potential. To place the
individual’s capabilities in a realistic framework SCDP’s
central mottos are ‘Can’, ‘Will’, ‘Choose’, ‘Open up to
others’, and ‘Do’. SCDP’s message is that by exploring their
boundaries PwMS become more aware of their faculties,
and that the resulting self-management leads to higher
awareness of potentials and a better communication with
care professionals.
Components
SCDP’s components are 1) large group sessions, 2)
small group sessions, 3) consultations (carrousel), 4) a
theatre evening, and 5) start of the day with a joint
activity (optionally).
Large group sessions Plenary sessions: participants make
optimal use of their existing potentials, learn how to sup-
port and encourage other participants, and experiment
how to give the required feedback to the multidisciplinary
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team. Group sessions in which half the participants take
part: participants examine and identify which stressors
have to be addressed most, and formulate realizable indi-
vidual aims (one or two).
Small group sessions The small group sessions form
the actual training. Depending on their individual goals
the participants sign up for the training groups ‘Body’,
‘Feeling’ or ‘Life’, to work out their aims and to experi-
ment whether they can reduce their stressors. The Body
sessions focus on the exploration of the physical capabil-
ities and are coached by a physiotherapist. The Feeling
sessions focus on the exploration of the emotional poten-
tial and are coached by a psychiatrist and a psychiatric
nurse. The Life sessions focus on the exploration of
capabilities relating to the daily living with MS and are
coached by a neurologist, a registered nurse specialized in
MS, and a person with MS. In addition, there are relax-
ation sessions for those who have difficulties in experi-
encing their body: the Yoga session focuses on body
experience and relaxation, whereas the Physical session
focuses on relaxation through physical strain. The choices
between the various small group sessions are made inde-
pendently by the participants.
Consultations After having identified and formulated in
the large group sessions their individual stressors and
aims, the participants sign in for one or more group
consultations, during which they verify whether their
aims are realizable by asking the members of the multi-
disciplinary team for aim-related medical information.
Theater evening On the informal theater evening the
participants practice to change roles and show their po-
tentials by openly experimenting. They do their best to
perform before each other and the team. The jointly cre-
ated evening performance increases the cohesion within
the group and learns participants to find an equilibrium
between consuming and action.
Joint activity at the start of the day During an optional
joint activity (walk in the woods) at the start of the day
the participants experiment with physical challenges and
with the management of their energy.
Multidisciplinary team
The multidisciplinary team includes a psychiatrist, psychi-
atric nurse, neurologist, specialized MS nurse, physio-
therapist, yoga teacher, and a person with MS. The team
members respect and understand the participants’ individ-
ual qualities and differences, and they stimulate, defy and
confront them to explore and push their boundaries. Apart
from the consultations the team keeps to coaching, stimu-
lating and activating the participants. By participating in
all large group sessions the team members become
acquainted with the individual stressors and goals. Dur-
ing the consultations they have a professional and
informative role. In the small group sessions every dis-
cipline focuses on its own area of interest. During a tip
time at the end of each day the team members evaluate
the sessions, inform each other on the participants’ pro-
gresses and obstacles, discuss whether the participants
make optimal use of their opportunities, and monitor to
what extent the personal goals are being attained.
Study design and organization
The SCDP was given during three days in Zorghotel
Spelderholt, Beekbergen, the Netherlands, a facility espe-
cially equipped for the accommodation of people with im-
paired health. From March 2012 to December 2012 five
weekends were organized for PwMS and their significant
support partner (partner or informal caregiver), i.e. 8 to
10 couples per weekend. The SCDP was given from
Friday to Sunday.
The idea for a social cognitive intervention with partner
or other informal care giver (significant other) was con-
ceived by the National Multiple Sclerosis Foundation
(NMSF), Maassluis, the Netherlands (AvdZ) and further
developed in collaboration with PsyToBe (RR) and the
other team members. The weekends were organized and
managed by the NMSF, Maassluis, the Netherlands (MvD).
The observational study was conducted by the MS4
Research lnstitute, Nijmegen, the Netherlands (PJJ, MH).
PwMS and their support partners were recruited
through (a) announcements on the NMSF’s website www.
nationaalmsfonds.nl, (b) advertisements in ‘Nieuwslijn’, the
NMSF’s quarterly journal and (c) email messages to all
registered members of the NMSF. Those interested in partici-
pation contacted the NMSF by telephone. They were in-
formed on the study and its procedures, had their questions
answered, and underwent a screening interview and inclu-
sion procedure. The inclusion criteria were (a) definite MS,
(b) relapse free in the last 4 weeks, and (c) able and willing to
participate in the SCDP and the study-related assessments.
The study used paper-and-pencil self-report question-
naires that were sent by regular mail one week before the
weekend, and 1, 3 and 6 months after the intervention.
The questionnaires were accompanied by a stamped re-
turn envelope addressed to the MS4 Research Institute.
Outcomes and outcome measures
Self-efficacy and participation/autonomy were the primary
study outcomes. HRQoL, anxiety, depression, and fatigue
were secondary outcomes.
Primary outcome measures
Self-efficacy was assessed by the Multiple Sclerosis
Self-Efficacy Scale (MSSES). The MSSES is an 18-item,
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psychometrically validated, self-report questionnaire for
the assessment of self-efficacy [9]. The MSSES consists
of two 9-item subscales of Function and Control. Each
item is scored on a Likert-like scale form 10 (very un-
certain) to 100 (very certain) and addition of the re-
spective item scores yields the MSSES-Function score
and the MSSES-Control score, both ranging from 100
(minimum) to 1000 (maximum). The MSSES-Function
subscale measures confidence with functional abilities,
whereas the MSSES-Control subscale measures confi-
dence with managing symptoms and coping with the
demands of illness [9].
The Impact on Participation and Autonomy (IPA) ques-
tionnaire is a 32-item, psychometrically, validated, generic,
self-report instrument for the quantification of limitations
in participation and autonomy in people with chronic
health conditions [10,11]. The IPA-Limitations subscale
assesses perceived limitations in participation and auton-
omy in relation to 32 different life situations across five
subscales: autonomy indoors, family role, autonomy out-
doors, social life and relationships, and work and educa-
tion [10-12]. Items are rated on a 5-point scale from 0
(very good) to 4 (very poor), and a higher score indicates a
higher limitation to participation and autonomy. The IPA-
Problems subscale examines the extent to which these
limitations are experienced as problematic, by assessing
nine different areas of participation and autonomy: mobil-
ity, self care, activities in and around the house, looking
after money, leisure, social life and relationships, paid or
voluntary work, education and training, and helping and
supporting other people [10-12]. The perceived problems
are graded on 3-point scale ranging from 0 (no problem)
to 2 (severe problems), and a higher IPA-Problems score
indicates a greater experience of problems [10-12].
Secondary outcome measures
HRQoL was assessed by the Multiple Sclerosis Quality
of Life 54-Item (MSQoL-54) questionnaire [13]. The
MSQoL-54 is a psychometrically validated, MS-specific,
multi-dimensional inventory of patient-centered health
status, and consists of the Short Form 36-Item (SF-36)
health survey as a generic core measure, supplemented
with 18 questions on items relevant to PwMS in the
areas of health distress, sexual function, satisfaction with
sexual function, overall quality of life, cognitive function,
energy, and pain and social function [13]. The MSQoL-54
contains 52 items distributed into 12 scales, and two sin-
gle items. A physical and a mental dimension underlie the
MSQoL-54: the Physical and Mental domains [13]. Scores
for each domain range from 0 to 100, where higher values
indicate better HRQoL.
Anxiety and depression were measured by the Hospital
Anxiety and Depression Scale (HADS), a psychometrically
validated, 14-item, self-report questionnaire for anxiety
and depression [14]. The HADS consists of two subscales,
one for anxiety and one for depression, each comprising
seven questions. Each question scores 0 to 3 points, and a
total subscale score of 0 to 7 points indicate no anxiety/
depression, 8 to 10 points indicate possible mild to mod-
erate symptoms of anxiety/depression, and 11 to 21 points
indicate a probable clinically significant condition of anx-
iety/depression [14].
Fatigue was measured by the Multiple Sclerosis Fa-
tigue Impact Scale 5-Item Version (MFIS-5), a validated,
short questionnaire examining a patient’s perceived im-
pact of fatigue on a variety of daily activities over the
past month [15]. Answers to each question are rated on
a 5-point scale from 0 to 4. The MFIS-5 total score con-
sists of the sum of the raw scores on these 5 items and
ranges from 0 to 20, where higher scores indicate more
experienced fatigue [15].
Disability was measured by an assessment of the Ex-
panded Disability Status Scale (EDSS) score via telephone
[16]. The classical EDSS is based on a neurological exam-
ination that provides the basis for the assessment of sev-
eral functional systems that, according to predefined
algorithms, contribute to the EDSS score [17]. An EDSS
version for use by telephone via a structured interview has
been developed and validated [16].
Ethical aspects
The study protocol was submitted to and viewed by the
ethical review board “Medisch-Ethische Toetsing Onder-
zoek Patiënten” (METOPP), Tilburg, the Netherlands.
CCMO (Central Committee on Research Involving Human
Subjects) number: NL36051.028.11 (http://www.ccmo.nl/
en). The METOPP concluded that because of the observa-
tional design of the study a formal review by an ethical re-
view board was not required, as the study did not meet the
criteria stated in the Dutch Medical Research Involving
Human Subjects Act of 1999. The study was carried out in
compliance with the Declaration of Helsinki. Potential par-
ticipants were informed on the study by the NMSF and
two members of the multidisciplinary team (AH, PJJ). Pa-
tients who agreed to participate signed an informed con-
sent form. The SCDP constitutes an unusual mental and
physical pressure and might therefore lead to the tempor-
ary occurrence or worsening of MS symptoms, like fatigue,
mood alteration, or emotions. The continuous presence of
the experienced team guaranteed that unwanted changes
were rapidly noticed and adequately cared for.
Data analysis
For both primary and secondary outcomes the absolute
values at baseline and at 1, 3 and 6 months after SCDP are
described as mean with standard deviation (SD), and the
percentage changes from baseline at 1, 3 and 6 months
are described as mean with standard error of the mean
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(SEM). As our intention was to explore whether any
changes could be observed after SCDP (proof of concept)
and at what time points eventual changes were most
prominent, we choose to compare each outcome at each
time point with its baseline, by using multiple paired Stu-
dent T-tests. To better assess the degree and clinical rele-
vance of changes we tested for each outcome at each time
point the percentage change compared to baseline instead
of absolute values. Similar analyses were performed in
subgroups according to disease course (RR, progressive)
and degree of disability (EDSS < 4.0, EDSS > = 4.0). Differ-
ences in demographic and disease characteristics between
RR and progressive patients were tested with unpaired
Student T-tests. For all tests P-values <0.05 were consid-
ered significant.
Results
Participants
Ninety-four participants, 47 PwMS and their support
partners, were included in the study and participated in
a SCDP. Eighty-seven (92.6%) persons completed the pro-
gram, whereas seven persons (7.4%), being three couples
and one support partner, stopped prematurely. Reasons
for couples to discontinue were: knee symptoms in a per-
son with MS (1×), death of a close relative (1×), and re-
fusal of a partner to comply with the program (1×); one
partner left prematurely due to an exacerbation of pre-
existing marital problems. The drop outs occurred in the
1st (n = 2), the 3rd (n = 3) and the 4th (n = 2) SCDP week-
end. In five persons (5.1%) the discontinuation was con-
sidered SCDP-related.
Follow up data were obtained from 44 PwMS. Twenty
had a RR, 22 a SP, and two a PP disease course. The
demographic and disease characteristics are presented in
Table 1. As expected, the mean values for age, disease dur-
ation and EDSS score were significantly lower in the RR
group than in the progressive group (all P values <0.05).
Self-efficacy, participation and autonomy
The mean (SD) MSSES-Function, MSSES-Control, IPA-
Limitations and IPA-Problems values for the total group at
baseline and at 1, 3 and 6 months are presented in Table 2.
The mean (SEM) percentage changes from baseline at 1, 3
and 6 months in the total group are presented in Table 3.
Not a single change reached statistical significance.
HRQoL, anxiety, depression and fatigue
The mean (SD) MSQoL-54 (Physical, Mental), HADS
(Anxiety, Depression) and MFIS-5 scores for the total
group are presented in Table 4. The mean (SEM) per-
centage changes from baseline are shown in Table 5. In
the total group the MSQoL-54 Mental and Physical
scores had significantly increased at 6 months by 12.2%
and 10.2%, respectively, compared to baseline, whereas
the Mental scores were also significantly higher at 1 and
3 months (+16.0%, +13.3%) compared to baseline.
RR and progressive groups
The mean (SD) values of MSSES-Function, MSSES-
Control, IPA-Limitations and IPA-Problems scores in
the RR and progressive subgroups at baseline and at 1, 3
and 6 months are presented in Table 2, and the mean
(SEM) percentage changes from baseline at the various
time points are shown in Table 3. Similarly, the corre-
sponding values for Physical and Mental MSQoL-54,
HADS Anxiety, HADS Depression, and MFIS-5 scores
are given in Tables 4 and 5.
Table 1 Mean (standard deviation) (minimum-maximum)
values of demographic and disease characteristics of
PwMS participating in SCDP
Relapsing remitting
(n = 20)
Progressive
(n = 24)*
Male/female ratio 4/16 (1:4) 5/19 (1:3.8)
Age (yrs.)** 42.7 (10.1) (25–65) 48.7 (7.6) (30–60)
Disease duration (yrs.)** 8.4 (6.9) (1.2-24.2) 17.5 (8.6) (3.2-36.0)
EDSS score** 3.1 (1.2) (1.5-6.0) 5.5 (1.4) (3.0-7.5)
*, Secondary Progressive (n = 22) and Primary Progressive (n = 2); **, P < 0.05
for comparisons between Relapsing Remitting and Progressive persons.
Table 2 Mean (SD) values of Multiple Sclerosis Self-Efficacy Scale (MSSES) and Impact on Participation and Autonomy
(IPA) scores at 1, 3 and 6 months after SCDP in the total group and in the Relapsing Remitting (RR) and Progressive
(P) subgroups
Baseline 1 month 3 months 6 months
Total RR P Total RR P Total RR P Total RR P
MSSES-Function 66.45
(21.52)
81.80
(12.15)
53.59
(19.62)
66.28
(21.29)
81.70
(12.52)
54.09
(19.31)
64.47
(22.41)
74.75
(19.33)
54.23
(20.28)
66.10
(21.93)
81.30
(12.00)
50.94
(18.07)
MSSES-Control 47.79
(19.06)
57.01
(19.67)
41.63
(15.29)
49.33
(17.42)
58.04
(15.01)
43.84
(16.24)
49.64
(19.76)
53.52
(18.28)
45.50
(20.77)
55.05
(18.91)
64.26
(13.66)
46.18
(19.44)
IPA-Limitations 2.70
(0.57)
2.43
(0.57)
2.89
(0.50)
2.59
(0.63)
2.34
(0.53)
2.76
(0.65)
2.57
(0.62)
2.26
(0.51)
2.85
(0.56)
2.58
(0.67)
2.30
(0.55)
2.88
(0.64)
IPA-Problems 2.09
(0.36)
1.95
(0.36)
2.17
(0.32)
1.97
(0.46)
1.73
(0.39)
2.11
(0.43)
1.93
(0.52)
1.74
(0.48)
2.07
(0.54)
2.02
(0.51)
1.86
(0.52)
2.14
(0.48)
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In the RR group the IPA-Problems score had signifi-
cantly decreased (−8.4%) at 3 months and the MSSES-
Control score had significantly increased (+24.8%) at
6 months, whereas no changes in primary outcomes were
seen in the progressive group (Table 3). Moreover, in the
RR group the mean MSQoL-54 Mental score had in-
creased (+21.4%) at 1 month, and the Physical (+12.7%)
and Mental (+22.3%) scores at 6 months, which was not
the case in the progressive group (Table 5).
Low- and high-disability groups
In patients with EDSS < 4.0 the mean IPA-Limitations
and -Problems scores had significantly decreased (−6.1%,
−8.8%) at 3 months, whereas the MSSES-Control score
had increased (+23.8%) at 6 months (Table 6). In the
EDSS > =4.0 group there were no significant changes.
Moreover, at 1, 3 and 6 months the mean MSQoL-54
Mental score was higher than at baseline (+19.2%,
+21.5%, +19.3%) in the EDSS < 4.0 group, in contrast to
the higher EDSS group, where significant changes were
absent (Table 7).
Discussion
In an observational study we assessed in PwMS the effect
of a social cognitive wellness program with the participa-
tion of support partners on self-efficacy, participation and
autonomy (primary outcomes), HRQoL, anxiety, depres-
sion and fatigue (secondary outcomes). In the total group
a significant but moderate increase in mental HRQoL was
seen at 1, 3 and 6 months, whereas improvements in the
primary outcomes were absent. However, in the RR group
the MSSE-Control score had significantly increased by
24.8% (mean) at 6 months, and the IPA-Problems score
decreased by −8.4% (mean) at 3 months. Moreover, in RR
patients the mental and physical HRQoL had increased at
6 months by 21.4% and 12.7% resp., with no such changes
in the progressive group. These discrepancies between RR
and progressive patients were mirrored by the results of
the analyses according to degree of disability. Overall, our
findings indicate that 3 to 6 months after SCDP, persons
with RRMS or low disability may experience less limita-
tions with respect to participation and autonomy, an im-
proved confidence with managing symptoms and coping
with demands of their disease (self-efficacy-control), and
improved mental and physical HRQoL. Notably, the im-
proved mental HRQoL (mean increase MSQoL-54 Mental
score 22.3%) at 6 months is likely related to the improved
self-efficacy-control (mean increase MSSES-Control score
24.8%), since in chronic conditions the relationship be-
tween self-efficacy and psychological well-being has been
convincingly documented [6,3]. Moreover, the degree to
which both these measures had increased (>20%) suggest
Table 3 Mean (SEM) percentage changes from baseline in Multiple Sclerosis Self-Efficacy Scale (MSSES) and Impact on
Participation and Autonomy (IPA) scores at 1, 3 and 6 months after SCDP in the total group and in the Relapsing
Remitting (RR) and Progressive (P) subgroups
1 month 3 months 6 months
Total RR SP/PP Total RR SP/PP Total RR SP/PP
MSSES-Function 4.5% (4.1) 0.9% (10.0) 15.1% (47.2) −0.2% (5.2) 6.2% (21.9) 5.3% (51.1) 1.4% (4.8) 1.2% (12.9) 1.5% (40.7)
MSSES-Control 10.0% (6.1) 3.8% (30.0) 15.1% (47.2) 8.0% (8.4) −0.2% (33.9)% 15.5% (68.3) 23.4% (9.5) 24.8%* (37.2) 22.1% (75.2)
IPA-Limitations −4.1% (2.4) −3.8% (18.6) −4.6% (14.1) −3.3% (2.6) −6.3% (13.6)% −0.7% (18.8) −3.1% (2.8) −5.3% (19.3) −1.1% (15.9)
IPA-Problems −3.4% (2.5) −6.0% (17.0) −1.7% (15.2) −6.5% (2.9) −8.4%* (18.35) −4.9% (17.4) −2.2% (3.3) −3.9% (22.5) −0.8% (18.1)
*, P < 0.01.
Table 4 Mean (SD) values of Multiple Sclerosis Quality of Life 54-Item (MSQoL-54), Hospital Anxiety and Depression
Scale (HADS) and Modified Fatigue Impact 5-Item Scale (MFIS-5) scores at 1, 3 and 6 months after SCDP in the total
group and in the Relapsing Remitting (RR) and Progressive (P) subgroups
Baseline 1 month 3 months 6 months
Total RR P Total RR P Total RR P Total RR P
MSQoL-54
physical
46.3
(13.1)
52.0
(13.1)
42.6
(11.6)
46.9
(15.4)
53.7
(14.6)
41.9
(14.2)
47.9
(18.4)
52.2
(16.7)
41.6
(16.9)
49.6
(16.6)
57.1
(15.2)
40.9
(11.6)
MSQoL-54
mental
52.8
(13.4)
51.2
(13.1)
54.1
(13.8)
59.6
(14.3)
60.5
(15.2)
58.8
(13.7)
59.0
(14.1)
59.8
(14.3)
57.5
(14.3)
57.3
(15.1)
60.6
(13.3)
53.6
(16.1)
HADS
anxiety
7.67
(3.65)
6.78
(3.92)
8.35
(3.45)
6.59
(3.58)
5.39
(3.31)
7.41
(3.62)
6.56
(3.72)
5.67
(3.69)
7.45
(3.63)
6.53
(3.72)
5.11
(2.19)
7.81
(4.39)
HADS
depression
6.38
(4.25)
6.00
(4.52)
6.61
(4.20)
5.76
(3.83)
4.67
(3.55)
6.55
(3.97)
5.61
(3.51)
5.11
(3.55)
6.18
(3.47)
5.95
(4.27)
4.72
(3.49)
7.14
(4.68)
MFIS-5 12.43
(3.65)
12.72
(3.16)
12.09
(4.08)
11.73
(3.43)
11.00
(3.31)
12.19
(3.53)
11.29
(3.78)
10.94
(3.59)
11.77
(3.95)
11.88
(3.49)
11.89
(3.55)
12.05
(3.50)
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that the observed changes are clinically relevant and do
qualify as improvements.
Self-efficacy, being the belief in one’s ability to produce
outcomes one wants [1,3], is a strong predictor of health
behavior, and it can be instrumental in modulating the
experience of chronic illness [18,3]. Various interven-
tions have been developed to increase self-efficacy with
the goal of improving chronic disease outcomes [3,19].
Some interventions have focused on a single behavior
such as exercise or stress management, while others have
taken a more comprehensive “lifestyle” approach [20,21].
In the U.S.A. a concentrated 4-day interdisciplinary educa-
tional wellness program has been developed for PwMS
[8]. For conceptual and practical reasons we modified this
program. We emphasized the social cognitive components
and therefore only investigated couples of PwMS and their
support partners. In addition, for reason of efficiency and
to save time for the participants, notably the support
partners, we condensed the program to 3 days by reducing
the educational component. The beneficial changes after
SCDP in the RR group are in line with the effects ob-
served by Ng et al. after the 4-day original CDP [8]. These
authors observed in MS patients (N = 98) improvements
in self-efficacy control (MSSES-Control) and HRQoL
(Short Form 36-Items [SF-36]) at 1, 3 and 6 months [8];
comparisons between RR and progressive PwMS were not
reported [8]. Importantly and in contrast to our find-
ings, improvements in the study by Ng et al. were inde-
pendent from disability (EDSS). A comparison of their
subjects’ disability level (median EDSS 3.5) with that in
our RR (mean EDSS 3.1) and progressive (mean EDSS
5.5) groups, suggests that their participants were rela-
tively mildly disabled and most likely mainly RR.
The negative findings in the progressive group may relate
to several factors. The original CDP takes 4 days and con-
sists of the following six components: group-based individ-
ual assessments (general health, gait, spirometry, visual
acuity, muscle function, balance, coordination, fitness, ex-
ercise); group workshops (stretching, cognition, fatigue,
Swiss ball, mindful motivation); group seminars/lectures
(MS facts and treatment, MS research, sexual function,
communication, psychological aspects of MS, nutrition, ex-
ercise, stress management, complementary and alternative
medicine, goal setting); group optional activities (walking,
stretching/yoga/Pilates); individual consultations (neuro-
logical, psychological, program summary, goal setting); and
individual optional consultations (program integration and
skill building, speech language pathologist, occupational
therapist, aqua therapist, nurse practitioner, physiatrist,
dietician, urologist) [8]. It may be that the social cognitive
approach, the reduced educational component, or the con-
densation to 3 days have rendered our SCDP less effective
Table 5 Mean (SEM) percentage changes from baseline in Multiple Sclerosis Quality of Life 54-Item (MSQoL-54),
Hospital Anxiety and Depression Scale (HADS) and Modified Fatigue Impact 5-Item Scale (MFIS-5) scores at 1, 3 and
6 months after SCDP in the total group and in the Relapsing Remitting (RR) and Progressive (P) subgroups
1 month 3 months 6 months
Total RR SP/PP Total RR SP/PP Total RR SP/PP
MSQoL-54
physical
5.6% (4.7) 6.0% (5.0) 5.3% (8.2) 7.5% (6.2) 6.3% (5.9) 8.4% (10.7) 10.2%** (4.8) 12.7%** (5.5) 7.8% (8.0)
MSQoL-54
mental
16.0%* (5.0) 21.4%** (8.8) 11.5%** (5.4) 13.2%** (5.8) 22.3%*** (10.7) 5.5% (5.4) 12.2%** (6.0) 22.3%** (8.7) 3.2% (7.9)
HADS
anxiety
−3.9% (12.6) 1.9% (27.2) −9.9% (5.9) −1.1% (13.7) 1.7% (27.7) −3.5% (9.7) −2.4% (10.1) −2.6% (18.7) −2.3% (9.9)
HADS
depression
−3.4% (10.8) −22.6%*** (11.0) 13.2% (17.8) 36.3% (24.8) 10.3% (19.6) 58.8% (43.1) 14.0% (15.6) −10.6 (16.8) 36.3% (25.0)
MFIS-5 −2.2% (6.7) −0.5% (12.4) −4.0% (6.7) −2.6 (7.5) −2.3% (12.4) −2.9% (9.0) −0.33% (6.5) 3.0% (12.5) −3.5% (4.7)
*, P < 0.005; **, P < 0.05; ***, 0.05 < P <0.06 (comparisons with baseline).
Table 6 Mean (SEM) percentage changes from baseline in Multiple Sclerosis Self-Efficacy Scale (MSSES) and Impact on
Participation and Autonomy (IPA) scores at 1, 3 and 6 months after SCDP in PwMS with low disability (EDSS < 4.0) and
high disability (EDSS > =4.0)
1 month 3 months 6 months
EDSS < 4.0 EDSS > =4.0 EDSS < 4.0 EDSS > =4.0 EDSS < 4.0 EDSS > =4.0
MSSES-Function 3.2% (1.9) 5.4% (7.7) −2.7% (5.1) 1.9% (9.6) 2.5% (3.0) 0.2% (9.5)
MSSES-Control 6.5% (6.5) 13.3% (10.4) 5.8% (6.5) 11.0% (16.6) 23.8%* (8.1) 22.9% (17.7)
IPA-Limitations −6.3% (3.9) −2.0% (3.0) −6.1%** (3.0) −0.6% (4.3) −4.8% (4.0) −1.3% (4.0)
IPA-Problems −4.2% (4.2) −2.9% (3.1) −8.8%** (4.3) −3.7% (4.0) −1.3% (5.3) −3.1% (4.1)
*, P < 0.01; **, 0.05 < P < 0.06 (comparisons with baseline).
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in persons with progressive MS. On the other hand, the
relatively small numbers of participants in our study may
have prevented the detection of small beneficial effects.
Depression and anxiety are common in PwMS. Peo-
ple’s mood can be significantly affected by the percep-
tion of their disability [22], and in a recent cohort study
in PwMS it was shown that experiencing depression sig-
nificantly predicted anxiety [22]. In our study we only
observed in the RR group a tendency to a temporary
decrease in the depression score (−22.6%) at 1 month.
Changes on the longer term were not seen. Neither was
the level of fatigue (MFIS-5) affected by SCDP.
With greater loss of mobility, the ability to perform ac-
tivities of daily living decreases and the dependence
upon the assistance of others increases [23,24]. In the
RR group the MS-related limitations, and the extent to
which these limitations were experienced as problematic,
were decreased at 3 months, but not at 6 months. This
finding suggests that the effect of a single SCDP inter-
vention may be temporary, and that follow-up sessions
should be considered.
Given the uncontrolled design of the study we cannot
infer that SCDP caused the changes that we observed.
Yet, a placebo effect and a regression to the mean seem
insufficient explanations for the improvements at 3 or
6 months, as virtually no changes were seen in persons
with progressive MS. Another limitation of our study is
the relatively small number of PwMS studied.
Conclusions
Our findings suggest that in PwMS with a RR disease
course or low disability, an intense multi- and interdiscip-
linary, 3-day, social cognitive wellness program with the
participation of support partners, may lead to improve-
ments in self-efficacy-control, and mental and physical
HRQoL 6 months later. The data also suggest that social
cognitive wellness programs involving support partners
may enhance autonomy and participation. To be optimally
effective, social cognitive wellness programs for persons
with a chronic disease may have to be differentiated ac-
cording to type of disease or degree of disability. Actually
we conduct a randomised controlled trial on the effective-
ness - in terms of self-efficacy, autonomy and participa-
tion, and HRQoL - of SCDP in persons with RRMS and
low disability (EDSS < 4.0). Its primary endpoint, the mean
of the MSSES-Control scores at 3 and 6 months, is based
on the observational data from the present study.
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